<SEC-DOCUMENT>0001640334-17-000093.txt : 20170113
<SEC-HEADER>0001640334-17-000093.hdr.sgml : 20170113
<ACCEPTANCE-DATETIME>20170113165516
ACCESSION NUMBER:		0001640334-17-000093
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170113
DATE AS OF CHANGE:		20170113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nemus Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-206992
		FILM NUMBER:		17528443

	BUSINESS ADDRESS:	
		STREET 1:		600 ANTON BLVD, SUITE 1100
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626
		BUSINESS PHONE:		(949) 396-0330

	MAIL ADDRESS:	
		STREET 1:		600 ANTON BLVD, SUITE 1100
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>nmus_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<html><head><title>nmus_424b3.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right"><b>Filed Pursuant to Rule 424(b)(3)</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="right"><b>Registration No.&nbsp;333-206992</b></p><p style="MARGIN: 0px" align="center">&nbsp; </p><p style="MARGIN: 0px" align="center"><b>PROSPECTUS SUPPLEMENT NO. 7</b></p><p style="MARGIN: 0px" align="center"><b>(To Prospectus Dated April 22, 2016)</b></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="center"><img src="nmus_424b3img1.jpg"></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="center"><b>NEMUS BIOSCIENCE, INC.</b></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px" align="center"><b>Up to 14,804,163 Shares of Common Stock</b></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">This prospectus supplement no. 7 supplements the prospectus dated April 22, 2016,&nbsp;relating to the resale by the selling shareholders identified in the prospectus of up to&nbsp;14,804,163 shares of our common stock, $0.001 par value, including (i)&nbsp;8,125,000 shares of common stock, which equals 130% of the maximum number of shares of common stock issuable upon the conversion of shares of our Series B convertible preferred stock, par value $0.001 per share (&ldquo;Preferred Stock&rdquo;) and 6,250,000 shares of common stock issuable upon exercise of the warrants which we sold to investors in a private placement on August 20, 2015,&nbsp;(ii) 187,500 shares of common stock issuable upon exercise of warrants issued to our placement agent and (iii) 241,663 shares of common stock which we sold to investors in a private placement on January 7, 2015. </p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">This prospectus supplement incorporates into our prospectus the information contained in our attached Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on January 13, 2017.</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; BACKGROUND: white; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">You should read this prospectus supplement in conjunction with the prospectus, including any supplements and amendments thereto. This prospectus supplement is qualified by reference to the prospectus except to the extent that the information in the prospectus supplement supersedes the information contained in the prospectus.</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including any supplements and amendments thereto.</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b>You should carefully consider matters discussed under the caption &ldquo;Risk Factors&rdquo; beginning on page 4 of the prospectus.</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">&nbsp;&nbsp;</p><p style="MARGIN: 0px" align="center">The date of this prospectus supplement is January 13, 2017.</p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px"><table id="pagebreakf66cca3e-430a-47a6-982e-eb8be00a5659" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN: 0px" align="center">&nbsp; </p><p style="MARGIN: 0px" align="center"><b style="MARGIN: 0px"><font size="3">UNITED STATES</font></b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="3">WASHINGTON, D.C. 20549</font></b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b>CURRENT REPORT</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">Date of Report (Date of earliest event reported): <strong><u>January 10, 2017</u></strong></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">&nbsp;<u>   <p style="MARGIN: 0px"><p style="MARGIN: 0px" align="center"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="50%" align="center" border="0" >    <tr height="15"><td style="BORDER-BOTTOM: 1px solid"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><b><font size="5">Nemus Bioscience, Inc.</font></b></p></td></tr><tr height="15"><td><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">&nbsp;(Exact name of registrant as specified in its charter)</p></td></tr></table></u><u></u></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0" >    <tr height="15"><td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>Nevada</strong></p></td><td valign="top" width="5%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><strong>&nbsp;</strong></p></td><td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>000-55136</strong></p></td><td valign="top" width="5%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><strong>&nbsp;</strong></p></td><td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><strong>45-0692882</strong></p></td></tr><tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">&nbsp; (State or other jurisdiction of incorporation)</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(Commission File Number)</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">&nbsp;(IRS Employer Identification No.)</p></td></tr></table></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center"><u><strong>600 Anton Boulevard, Suite 1100, Costa Mesa, CA 92626</strong></u></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(Address of principal effective offices) (Zip Code)</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center">Registrant's telephone number, including area code: <strong>(949) 396-0330</strong></p><p style="MARGIN: 0px" align="center">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">___________________________________________________</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="center">(Former name or former address, if changed since last report.)&nbsp;</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Wingdings">&#168; </font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Wingdings">&#168; </font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify"><font style="FONT-FAMILY: Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px" align="justify">&nbsp;</p><p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="MARGIN: 0px" align="justify">&nbsp;   <table id="pagebreak71a17ccc-dafe-490c-85a1-0bd095afef4a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><b>Item 1.01&nbsp; &nbsp; Entry into a Material Definitive Agreement.</b></p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">On January 10, 2017, Nemus Bioscience, Inc. (the &ldquo;Company&rdquo;) entered into a license agreement (the &ldquo;License Agreement&rdquo;) with the University of Mississippi, School of Pharmacy (&ldquo;UM&rdquo;), pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases. &nbsp;The License Agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA).&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">We are obligated to pay UM upfront license fees under the License Agreement. Under the License Agreement, we are also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones and royalties on net sales of licensed products sold for commercial use.&nbsp; The aggregate milestone payments due under the License Agreement if the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the&nbsp;mid-single digits. We must also pay to UM a portion of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. Our royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">The License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of our payment obligations under the license. UM may terminate the License Agreement, effective with the giving of notice, if: (a) we fail to pay any material amount payable to UM under the License Agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) we materially breach any covenant, representation or warranty in the License Agreement and do not cure such breach within 60 days after UM notifies us of such breach, (c) we fail to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) we are subject to a bankruptcy event, (e) we dissolve or cease operations or (f) if after the first commercial sale of a product during the term of the License Agreement, we materially fail to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of 1 year, other than for reasons outside our control. We may terminate the License Agreement with sixty days written notice to UM.</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p><p style="MARGIN: 0px">The foregoing description of the License Agreement is not complete and is qualified in its entirety by reference to the text of the License Agreement, a copy of which will be filed as an exhibit to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table id="pagebreak1451a25b-ccfc-4b2f-acfc-f21acb175c10" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid"><p style="MARGIN: 0px" align="center">&nbsp;2</p></td></tr><tr></tr><tr><td><div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr><tr><td>&nbsp;</td></tr></table></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px" align="center"><b>SIGNATURES</b></p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="MARGIN: 0px">&nbsp;</p><p style="MARGIN: 0px"><table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td valign="top" colspan="2"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><b>Nemus Bioscience, Inc.</b></p></td><td valign="top"></td></tr><tr height="15"><td valign="top" width="50%"></td><td valign="top" width="3%"></td><td valign="top" width="35%"></td><td valign="top" width="12%"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td></tr><tr height="15"><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Date: January 13, 2017</p></td><td><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px"><i>/s/ Elizabeth Berecz</i></p></td><td valign="top"></td></tr><tr height="15"><td valign="top"></td><td valign="top"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">&nbsp;</p></td><td valign="bottom"><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Elizabeth Berecz</p><p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; MARGIN-RIGHT: 0px">Chief Financial Officer</p></td><td valign="top"></td></tr></table></p><p style="MARGIN: 0px">&nbsp;   <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0" >    <tr><td class="hpbhr">&nbsp;</td></tr><tr><td style="BORDER-BOTTOM: black 1px solid"><p style="MARGIN: 0px" align="center">3</p></td></tr><tr></tr></table></p><p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>nmus_424b3img1.jpg
<TEXT>
begin 644 nmus_424b3img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C 5H# 2(  A$! Q$!_\0
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MU-)KOB+6XO C7>G!VNTN!%+-'%O9(^I?'Y#-9ND:E;^(="N-7O;9XKN"<17
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M1@JC\362WC+PXC%6UJRR/24&@')+<WJ*P?\ A-?#7_0:L_\ OZ*/^$T\-_\
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M8?\ D:;'_KS_ /9S0:XK^&</I@']KV!Q_P O,?\ Z$*^GI9%AA>1SA54L3Z
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M_(\DN?\ CTF_ZYM_*OJFS_X\8/\ KFO\A7RM=?\ 'K-_US;^5?5-G_QY0?\
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M56A>E&78XD3S"S:T$A^SM*)6C[%P" ?R-,2-YI$AB7=)(P1 .Y)P/YTE=?\
M#31O[6\813NN8+!?M#'_ &NB#\\G_@-!RPBYR2.]\5Z6FC?"BXTY.1!;QJ3Z
MG<,G\\FO$^QKW[XD?\B!JG^XO_H8KP'L:#HQ*M)(]S^$_P#R)4?_ %WD_G6%
M\9_NZ/\ [TG\A6[\*/\ D2H_^N\G\ZQOC+"YL])N #Y:RNC''0D#'\C0;R_@
M'C]S_P >LW_7-OY5]461!L;?'_/-?Y"OEP].G6NITWXA>(]+L8;*&>"2&)0D
M9FBRP4=!D'F@YL/5C3;N?0E>)_%\C_A*K'_KR_\ 9S53_A:WB?\ O67_ 'X/
M^-<MJ>J7NL:@]_?S>;.P"Y P%4= !V%!I7Q$)PLAFF?\A:Q_Z^8__0A7U$.E
M?,6B0O=>(-,@C&6DNHP/^^A7TU(2L+,.H4D4%X/X6/VBHC;PDDM#&2>I*BO#
M3\5?$X9@&LN"0/W!]?K2_P#"UO%']ZR_[\'_ !H+^L4SW'[-!_SPB_[X%>$_
M$FPM;#QBPM84B6>W2614& 6R1G [G J3_A:WB?\ O67_ 'X/^-<MJ>IWFLZC
M+?ZA,9;B3 +8P !T '84&%>O"<;(?H?_ ",6E_\ 7W'_ .A5]+U\U^'8FF\4
M:5&@RS7<>/SS7TI3'1^$GKF]3\.64DMQJ=K8PC5FB*)<A</TQU]<<9ZUTE&*
MSE'FBX]SO:3W/-=(ADTZ\^V7J_8[.$$7$D_R)CIM.>O-<7\2FED\7I(S![-[
M2,V+*<H8^^W''WNOMM]J]B\1>'K/Q+I+:=>&58RP</$V&5AT/->=_%"SM]%\
M-Z#I%ID00NP0,<MM5.Y_&L*&'C25D[G-B(OD?8K_  =%V-;U(Q[_ +']G7S?
M[OF;OE_'&?PK-^(_AN31=>DU%'5K7496=!_$CXRPQZ5G^'-:N_!VO6]VP9K6
MY@C>:,=)(7&X,/<<_D172?%;48+]]!:VE62&2"2=&4\$-MP?T-=1SWBZ%GNB
M'X;Z1%9NWBF_G6.WC#P6Z#EF8\,<?AQ4WCSP]?Z_JB:]HT+W]O+$L,D<8^>-
MESV/UK1^'FG)K7@B2U:0QO!>NR,!G!('^->@:+I*:39F%9#(S-N=B,9-<_-4
M]M:WNVW\SHITE*DHG)_#+PSJ.AV5Y<:E&89;IE*P%LE0,\GWYKT#%+BBN@Z(
M04(V1Y;\4= U?6M3TR33+&2Y2*&17*$?*2RXZ_0UQ$/@?Q0+B%FT:< 2*2=R
M\#(]Z^AV9$^\P&?4TU9(V.%93[ T&$\/&4N9L<@^0 ^E5KZRM]1LIK.ZC66"
M9"CHPZ@U;[44'1;2Q\_^(_A[K.B7CBSM9[^Q8_NY(5W,H]&'7/O6EX!\$ZI)
MXAM=3U&REM+.T;S%$R[6D?'RX'7 /.3Z5[9E2<9&1U]J=Q0<ZPT%+F0=J\M\
M:?#2;4M1EU716C$TQWSVTAVAF_O*>Q/?->I5&98P<%U!'8F@UG",U:1\\-X$
M\5HQ4Z-,<'JKJ1_.D_X07Q3_ - 6X_[Z7_&OHJEQ08?5(=SYT_X07Q3_ - 6
MX_[Z7_&MSP=X3\0Z?XQTV[O-*FBMXG8O(Q7"C8P]?4BO;^.M1>;$>DB'T^84
M#CAH1=[G-_$'3[O5/!-_9V,+37$ABV1J>6Q*A/Z UX[_ ,(+XI_Z MQ_WTO^
M-?1E&/:@NK0C4=V<C\/-.O=*\(6]I?V[07"R2$QMC(!8D5)XW\,GQ-X?>UB*
MK=1,);=FZ;AV/L1Q73LZ*/F8+GIDXH5T?.UE;UP<T&G(N7D/FQO"OB-+G[.=
M#O\ SLXP(LC_ +ZZ8KV3X?\ AIO#.ALMT%^W73^;<;3D+V5<^W\R:[+%(2 ,
MG@"@RI8>--W1S'CNQNM1\&:C9V,#3W$BJ$C4\GY@:\;_ .$%\4_] 6X_[Z7_
M !KZ+X(R/PI<4#JT(U'=G'_#K3+W2?"D=MJ%N]O.)G8QL1G!/'2M;Q%H5KXA
MT:;3;O(2095U^]&PZ,/I6P65022 !U)I!+&QPKJ3Z T&B@E'E/ M1^&_B:PF
M98K1;R/.%EA<<_\  3R*I_\ ""^*?^@+<?\ ?2_XU]&48H.=X2%SYS_X07Q3
M_P! 6X_[Z7_&E'@3Q4QP-&G&>Y9?\:^@XW20;D96 )7(YY!P1^>:EW D@$<=
M?:@/J<.YYIX$^'L^BWXU;5C']J12(($.X1YZL3W...*](E!,+J!DE2 *FH..
M],Z(4U"/*CYS/@7Q3N8C19_O''S+Z_6C_A!?%/\ T!;C_OI?\:^B#+&#@N@Q
MUR:<,$9%(Y_JL'U/G7_A!?%/_0%N/^^E_P :='X"\52.%&CRKGNSJ!_.OHG%
M-+!1DD #N30'U.'<\Z\"_#Q]#O%U357CDO54B**/E8L]3GN>U>C\4T21L<*Z
MD^@-/H.B$(P5D+11106-QQ7C7QCN-VN:5;9_U=M)(1_O,!_[*:]FKQ?XC:/K
M&J^,3+::9=3V\5I'$LD<>03EV/\ Z$*#GQ%_9V11U31_[1^&6AZY"N9K!&MY
MB.IBWD?^.L ?Q-<6]Q-+##"\K-% "L2D\("<D#VSSBO</ &ES?\ "!G2M5LY
M(@9)XWBE7!9&8G_V8UY5?^#=<L=2N;6+3+N>.&0JDJ1DAU['\J#DK4W9275'
MH'P:ESI>J0]UN5?\T _I7I]>6_"?3M1TV?58[ZQN+99!&R&5-H8C.<?I7J5!
MVX>_LU<6BBB@V.*\<_V?]HT+^U8XI+/[6WF)*F]3^[;&1WK#O?\ A$A<Z:/#
MUO;0ZHU[$(FM8#"V-WS G R-N<@UU'B=9XK[1+V*TN+F.VN6:58$W, 489Q]
M35'5KZ?7%LK.UT34(V%W%*9;B$1I&JMDG.>O'2@RDM6=N.E%(*6@U.9T?_D=
MO$?^[:_^@&NEKG=,MKB+Q;KEQ)"RPS+;^4Y'#X4YQ]*Z*@2V,_5I'AT:]EC8
MK(EO(RL.H(4X-<OH7@[P[<^&]-FGT>RGFEM8Y))9H@[NS*"6+'DDD]<UUFHQ
M/=:9=V\>-\L+HN?4@BN9T;7I].T.PL[K0M7%Q;VZ0R!+?<-RJ <$'D<=:"96
MOJ6O V1X5MXRSLL,UQ#'O8L0B3.JC)YX  _"NHKF_"-O<V/AR"*\A,$[233-
M$2"4#RLX!QW 89KI*!Q^%'(^.H_,T2 31RR6(O8#>K&&.8-WS9 Y(Z9]JHZ>
MOP_EU*V6TLM,2[:0& _9/+.\<C:2HY[UUFI7WV"U,WV6XN?F"^7;IO;GOCTK
ME]8O)]=@M-/M-&U"-S>V\S37$(C2)8Y5=FSGKA2,#UH)DM;G<#I2T@I:#0X:
M'1M-USQ?KIU2RAO?LWD1P+<+O6-2F2%!X&372:9H6E:/YG]FZ=:VGFX\SR(@
MF['3.*PQ/<Z+XGU6XDTR]N;>^$3Q2VL>\ JNTAAG@UN:;JW]H^9_H-[:^61_
MQ\Q;-V?3GF@B-OF:E97B7_D5M5_Z])?_ $$UJUDZ]%)<>'=1AB4O));2*BKU
M)*G H*>S+&B_\@/3_P#KVC_]!%7JHZ4KQZ19QR*5=($5E/4$**O4 MCA?&']
MG'7-!BUIT;32MS))%+DQO( FS<O\6,MC-6-!'@K^UD.B6^G)?A&*M!;['V]^
M<=*D\0_:+;Q#HVIQV<]U! MQ%,D"AG7S FUL=QE<?C6E8:VEY=K;KI6H6Y*D
M^;/;[$&/?-!'VC=HHHH-#SCPQ=3:+J$QFD9M.U;5+U%+'B"X6YD 'L' _,>]
M=#X?_P"1G\4_]?D/_I/'5;3="6_\*7VEZC#)$)[Z]=3T=-US(R.I['D,#3/!
M=OJL5QK;ZS"4NWNHU:4#"3[(D3S%]FVYQVSB@R2::1V-8?BJ:6W\*ZM-#(T<
MJ6<K(ZG!4A3R/>MRLGQ%9RZAX=U*SMP#-/;21H"< L5(%!I+8P]-\%^&9-)L
MV?0;"1F@0LTD"LS$@9))Y)]S750PQVT*11(J1HH5448"@= !7+V'B-[?3K:*
M;0=962*)4=1;9 (&#SGGZUU$,OG0QR[63>H;:XP1GL1ZT$PMT+%<+XK_ +';
MQ1IL6N>4]B+65UBG!:,R94 E>A.,]:[HUR.L_:++Q)8:JMA<7=JMO)!(+= [
M(200<9Z<'I0$]@\/#P=_:1.@V^GI>>6<M!!L;;WYQ]*ZZL73M86]NC"NEW]L
M=I;S)[?8OTSFMN@<=@HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
